Mirvetuximab soravtansine in ovarian cancer therapy: expert opinion on pharmacological considerations
Crossref DOI link: https://doi.org/10.1007/s00280-023-04575-y
Published Online: 2023-08-18
Published Print: 2024-02
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Nwabufo, Chukwunonso K. http://orcid.org/0000-0002-1889-0334
Text and Data Mining valid from 2023-08-18
Version of Record valid from 2023-08-18
Article History
Received: 5 June 2023
Accepted: 3 August 2023
First Online: 18 August 2023
Declarations
:
: CKN was a former employee of Gilead Sciences. CKN is employed by OneDrug.